Protein Kinase C Inhibitors Reduce SARS-CoV-2 Replication in Cultured Cells

作者：Changbai Huang, Fei Feng, Yongxia Shi, Wenhui Li, Ziqiao Wang, Yunkai Zhu, Shuai Yuan, Dandan Hu, Jun Dai, Qiqi Jiang, Rong Zhang, Chao Liu, Ping Zhang · 发表于：Microbiology Spectrum · 年份：2022 · DOI：10.1128/spectrum.01056-22 · 被引用次数：28 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、Vitamin C and Antioxidants Research

There is an urgent need for effective therapeutic drugs to control the pandemic caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). We found that several inhibitors of protein kinases C (PKCs) dramatically decrease the replication of SARS-CoV-2 in cultured cells. These PKC inhibitors interfere with an early step of viral infection. Therefore, the rapid and prominent antiviral effect of PKC inhibitors underscores that they are promising antiviral agents and suggests that PKCs are important host factors involved in infection by SARS-CoV-2.